---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021275"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:57:43.232760+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics reports Q1 net loss of $15.3M; Phase 2/3 trial enrollment on track

## Summary
- Net loss of $15.3M for Q1 2023, compared to $7.7M in Q1 2022.
- R&D expenses $12.0M (up from $5.6M); G&A expenses $4.1M (up from $2.1M).
- Cash, cash equivalents and investments totaled $88.5M at March 31, 2023.
- Nearly 80 clinical sites active in pivotal Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease.
- Expects to complete Phase 2 enrollment mid-2023; top-line data ~9 months after enrollment completion.

## SEC filing metadata
- accession: 0000950170-23-021275
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000095017023021275/0000950170-23-021275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000095017023021275/antx-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021275
- JSON: https://secwatch.observer/filing/0000950170-23-021275.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021275.txt

## Key facts
- Earnings Releases
  AN2 Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income $15.3 million.
  - Period: the quarter ended March 31, 2023
  - Net income: $15.3 million
  - Result: reported results
  source text: Net loss was $15.3 million for the three months ended March 31, 2023, compared to $7.7 million in the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000095017023021275/0000950170-23-021275-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.